Around 20,000 Americans are affected by acute myeloid leukemia (AML) each year. AML is a type of cancer that originates in the bone marrow and rapidly enters the bloodstream. Additionally, many individuals are impacted by myelodysplastic syndromes (MDS), which are blood disorders that result in the improper formation or functioning of blood cells.
The California Institute for Regenerative Medicine (CIRM) recently awarded $8 million to Rochelle Emery, MD, at Senti Bio to advance a clinical trial for a novel therapy targeting AML and MDS. Both cancers have a five-year survival rate of about 32 percent. Patients with recurring and relapsing AML face a bleak prognosis, with a median survival of three to six months despite various chemotherapy approaches or clinical trial treatments.
CIRM’s award will support the development of a new therapy that utilizes gene-modified logic-gated natural killer (NK) cells to help the patient’s body fight these cancers. This unique and more targeted approach offers a durable and effective solution, aiming to increase the median life expectancy for patients with recurring or relapsing AML.
“We are excited to advance clinical research for AML and MDS, for which limited treatment options exist,” says Dr. Abla Creasey, Vice President of Therapeutics Development at CIRM. “This innovative therapy holds great promise for improving treatment outcomes and providing new hope to patients facing these challenging conditions.”
CIRM remains committed to advancing groundbreaking science to deliver transformative regenerative medicine treatments equitably. The development of this novel NK cell therapy represents a significant step forward in achieving this mission, offering hope and promising relief to those affected by AML and MDS.
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://blog.cirm.ca.gov/2024/09/23/cirm-supports-gene-therapy-for-aml-and-mds/